4.7 Article

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

Related references

Note: Only part of the references are listed.
Editorial Material Medicine, General & Internal

Intensive glycemic control in the ACCORD and ADVANCE trials

Robert G. Dluhy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Letter Public, Environmental & Occupational Health

Studies of diabetes, thiazolidinediones, and coronary heart disease

Alexander M. Walker et al.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)

Article Medicine, General & Internal

Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis

Philip D. Home et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Medicine, General & Internal

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes

Steven E. Nissen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Endocrinology & Metabolism

Cortisol secretion in patients with type 2 diabetes - Relationship with chronic complications

Iacopo Chiodini et al.

DIABETES CARE (2007)

Review Cardiac & Cardiovascular Systems

Postprandial Hyperglycemia/Hyperlipidemia (Postprandial dysmetabolism) is a cardiovascular risk factor

James H. O'Keefe et al.

AMERICAN JOURNAL OF CARDIOLOGY (2007)

Review Clinical Neurology

The involvement of dopamine in the modulation of steep and waking

Jaime M. Monti et al.

SLEEP MEDICINE REVIEWS (2007)

Review Peripheral Vascular Disease

Sympathetic overdrive and cardiovascular risk in the metabolic syndrome

Guido Grassi

HYPERTENSION RESEARCH (2006)

Article Endocrinology & Metabolism

The burden of mortality attributable to diabetes - Realistic estimates for the year 2000

G Roglic et al.

DIABETES CARE (2005)

Article Endocrinology & Metabolism

Thiazolidinedione use, fluid retention, and congestive heart failure

RW Nesto et al.

DIABETES CARE (2004)